

Earnings Release for the Quarter ended June 30, 2014

Chennai, India – Thursday, August 07, 2014: TAKE Solutions Ltd. [BSE: 532890 | NSE: TAKE], a leading global business technology company with domain expertise in Life Sciences (LS) and Supply Chain Management (SCM), today reported its consolidated financial results for the quarter ended June 30, 2014.

HIGHLIGHTS FOR THE QUARTER ENDED JUNE 30, 2014

- *Operating revenue stood at INR 1,615 million (USD 27.0 million) compared to INR 1,967 million (USD 31.7 million) in Q4 FY14 and INR 1,957 million (USD 35.1 million) in Q1 FY14.*
 - *Total Revenue from continuing businesses increased 13.3% q-o-q*
- *Operating EBITDA was INR 313 million (USD 5.2 million) compared to INR 352 million (USD 5.7 million) in Q4 FY14 and INR 353 million (USD 6.3million) in Q1 FY14*
- *EBITDA margin was 19.4% compared to 17.9% in Q4 FY14 and 18.0% in Q1 FY14*
- *Net profit at INR 130 million(USD 2.2 million) compared to INR 129 million (USD 2.1 million) in Q4 FY14 and INR 132 million (USD 2.4 million) in Q1 FY14*
- *EPS at INR 1.08*

THREE MONTHS ENDED JUNE 30, 2014

For the three months ended June 30, 2014, TAKE Solutions' consolidated operating revenue was INR 1,615 million, a decline of 17.5% y-o-y and 17.9% q-o-q due to discontinuation of few businesses. Total revenue from continued operations increased 13.3% q-o-q due to healthy growth in LS business.

In Q1 FY15, EBITDA margins increased to 19.4% from 17.9% in Q4 FY14 and 18.0% in Q1 FY14 due to discontinuation of low margin SCM businesses during the quarter. EBITDA was INR 313 million, a decrease of 11.3% y-o-y and 11.1% q-o-q.

Net margin improved to 8.0% during the quarter compared to 6.6% in the last quarter of FY14 and 6.8% in the quarter ended June 30, 2013 due to higher operating margin. Net Profit during the quarter was INR 130 million, a 0.8% increase over Q4 FY14 and a decline of 1.9% over Q1 FY14. The diluted EPS for the period was INR 1.08.

MANAGEMENT COMMENTS

In line with our strategy outlined at the start of FY 14, we are witnessing a positive impact on the growth of the Life Sciences business. This growth can be attributed to an improvement in the funding environment for biotechnology companies and an increased focus on enhancing drug development efficiency. Due to these changing dynamics, revenue from continuing business has registered a healthy growth and the margins have improved. However, the decline in revenue was due to a divestment in the SCM business. We continue to streamline our businesses to improve

profitability and increase our investment in understanding the best market opportunities and clients' needs. This will enable us to achieve a strong position in the LS and SCM businesses.

NEW OFFERINGS

- TAKE announced the next release of OneSCM, a leading SaaS-based supply chain collaboration software solution focused on helping mid-market companies manage their extended supply chain operations. The latest version, OneSCM Enterprise 7.4, showcases a new user-interface designed to decrease end-to-end transaction time for Procurement Collaboration, AP Automation, Shipment Collaboration and Demand/Forecast Collaboration tasks.




PARTNERSHIP

- TAKE Life Sciences has become the first Generis Platinum Implementation Partner for Generis' CARA product, the market-leading user interface software for Documentum.

FY 15 Guidance

- FY15 Total revenue to be in the range of INR 7,350 million to INR 7,500 million
- FY15 PAT to be in the range of INR 530million to INR 560 million

GROWTH TRENDS



OPERATING METRICS

Revenue			
	Q1 FY15	Q4 FY14	Q1 FY14
INR Million	1,615	1,967	1,957
Y-o-Y growth (%)	-17.5%		
Q-o-Q growth (%)	-17.9%		
USD Million	27.0	31.7	35.1
Y-o-Y growth (%)	-23.0%		
Q-o-Q growth (%)	-14.9%		

Revenue by Vertical		
%	Q1 FY15	FY 14
SCM	30%	39%
LS	61%	53%
Others	9%	8%
Total	100%	100%

Revenue by Geography		
%	Q1 FY15	FY 14
US	68%	60%
Asia	24%	35%
RoW*	8%	5%
Total	100%	100%

*Rest of World

Revenue Concentration		
%	Q1 FY15	FY 14
Top 5 Clients	19.4%	19.1%
Top 10 Clients	27.2%	26.8%

Order Book		
USD MN	Q1 FY15	FY 14
LS	44.5	42.9
SCM	17.7	21.1
Total	62.2	64.0

Balance Sheet Summary		
	Q1 FY15	FY 14
Book Value per share (INR)	40.4	39.2
Net Worth (INR Mn)	4,844	4,700
Debt (INR Mn)	1,962	2,056
Cash & Cash Equivalents (INR Mn)	1,194	1,274
DSO	102	99
Net D/E (x)	0.2	0.2

Dollar Rates		
	Q1 FY15	FY 14
Period Average Rate	59.81	60.43
Period Closing Rate	60.05	59.86

CONSOLIDATED PROFIT AND LOSS ACCOUNT
FOR THE QUARTER ENDED JUNE 30, 2014

	Quarter ended			Year ended	
	30-June-14	31-Mar-14	30-June-13	31-Mar-14	31-Mar-13
Net Sales/Income from Operations	1,615	1,967	1,957	8,155	8,320
Expenses					
Cost of Sales	913	1,158	1,150	4,800	4,895
Other Expenses	389	456	454	1,883	1,811
	1,302	1,615	1,604	6,683	6,706
Profit Before Interest, Amortization, Depreciation & Tax	313	352	353	1,473	1,614
Product Development Expenses Written off	91	147	61	396	241
Depreciation	54	77	117	373	223
Profit before Interest & Tax	168	128	175	704	1,150
Finance Charges	27	30	32	138	144
Other Income	15	17	15	62	66
Profit before Tax	157	115	158	628	1,073
Tax	21	23	0	10	182
Profit before Minority interest	135	91	158	618	891
Minority interest	5	(38)	25	38	96
Net Profit	130	129	132	580	795
Basic Earnings Per Share (INR)	1.08	1.07	1.10	4.83	6.62
Diluted Earnings Per Share (INR)	1.08	1.07	1.10	4.83	6.61

About TAKE Solutions

TAKE Solutions, Ltd. [BSE: 532890 | NSE: TAKE] is a leading global business technology company with domain expertise in Life Sciences (LS) and Supply Chain Management (SCM). TAKE provides cost-effective and comprehensive solutions for enterprises across diverse sectors including pharmaceuticals, high technology, consumer packaged goods, oil/gas, and automotive. TAKE's SCM product suites include distinct technology with embedded IP that spans enterprise mobility, trading partner collaboration, and material tracking. In the LS domain, TAKE offers IP-based software and extensive knowledge-based solutions to enable efficient clinical, regulatory, safety and commercialization processes.

TAKE has been recognized as a 'Leader' in IDC Health Insights' "IDC MarketScape: Worldwide Life Science Drug Safety Services 2013 Vendor Assessment". TAKE's global headquarters is in Chennai, India; its U.S. headquarters is located in Princeton, New Jersey. TAKE has a proven track record as a trusted partner in delivering world-class solutions to more than 400 customers worldwide. For more information, please visit www.takesolutions.com.

Disclaimer:

Certain statements in this release concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, intense competition in IT including factors which may affect our cost advantage, wage increases, our ability to attract and retain highly skilled professionals, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in SCM & Life Sciences, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our contracts, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. TAKE does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the company.

For more details, please contact:

Sachin Garg

Investor Relations

HP: +91 – 99625 45467/ +65 – 929 79748

sachingarg@takesolutions.com